B+
Bull case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
MDXG
MiMedx GroupANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Surgical growth persists, Wound volume recovery translates into better sales and margins, and the Sanara transaction clears review. The second-quarter release supports the operating contrast, not confirmation of those future outcomes.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-28 · AMC.
What can break
FTC Second Requests leave the Sanara closing date and outcome uncertain. [#8-K-2026-10-16]
Momentum
53
Value
64
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.20 · Bull $5.50 · Bear $2.70Analysis 2026-10-25; returns require an exact persisted reference.
Earnings
2026-10-28 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.40
Why
Momentum53 · Δ7d -27.7
Value64 · Δ7d +0.8
Sentiment63 · Δ7d +13.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-28 · AMC.
- • Value remains the lead driver in the composite, 7D delta +0.8.
Contradictions & invalidation
- • FTC Second Requests leave the Sanara closing date and outcome uncertain. [#8-K-2026-10-16]
- • Medicare reimbursement changes materially reduced second-quarter Wound sales and gross margin. [#SEC-8K-2026-07-29]
- • Medicare reimbursement pressure continues to depress Wound pricing and gross margin, while antitrust review delays or prevents the proposed acquisition.
Catalyst clock
2026-10-28 · AMC
Third-quarter results on October 28
Lead driver: Value · See fundamentals
Momentum
53
8% active weight
Current posture
7d trendSoftening
Δ7d
-27.7
Δ21d
-21.1
Value
64
47% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
+0.3
Sentiment
63
45% active weight
Current posture
7d trendImproving
Δ7d
+13.4
Δ21d
+18.0
Why this grade
Composite grade A. Momentum 53.2 / Value 63.8 / Sentiment 63.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.20
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.70
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$561.18M
Beta
1.60
Shares Out
145.76M
P/E (TTM)
23.2
P/S (TTM)
2.38
P/FCF (TTM)
14.03
Rev YoY
-34.7%
EPS YoY
-255.9%
Gross Margin
+78.6%
Op Margin
+2.5%
Net Debt
-$143.59M
Current Ratio
5.33
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data